Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:ATCCode |
L01EB07
|
| gptkbp:CASNumber |
1110813-31-4
|
| gptkbp:chemicalFormula |
C24H25ClFN5O2
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:dacomitinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vizimpro
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
EGFR inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
rash decreased appetite stomatitis paronychia |
| gptkbp:target |
gptkb:epidermal_growth_factor_receptor
|
| gptkbp:bfsParent |
gptkb:dacomitinib
gptkb:Dacomitinib |
| gptkbp:bfsLayer |
7
|